Validation of Cancer-Type-Dependent Benefit From Immune Checkpoint Blockade in TMB-H Tumors Identified by the FoundationOne CDx Assay

Authors

D J McGrail
P G Pilié
N U Rashid
L Voorwerk
M Slagter
M Kok
E Jonasch
M Khasraw
A B Heimberger
N T Ueno
R Ferrarotto
J T Chang
S-Y Lin

Publication Date

11-1-2022

Journal

Annals of Oncology

DOI

10.1016/j.annonc.2022.07.009

PMID

35926816

PMCID

PMC10325933

PubMedCentral® Posted Date

7-7-2023

PubMedCentral® Full Text Version

Author MSS

Keywords

Humans, Immune Checkpoint Inhibitors, Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Biomarkers, Tumor

Published Open-Access

yes

Recommended Citation

McGrail, D J; Pilié, P G; Rashid, N U; et al., "Validation of Cancer-Type-Dependent Benefit From Immune Checkpoint Blockade in TMB-H Tumors Identified by the FoundationOne CDx Assay" (2022). Faculty, Staff and Student Publications. 4289.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4289